Karen O. Klein, MD

The panel examines potential long-term effects of central precocious puberty treatment on bone density and spermatogenesis in male patients.

Experts offer recommendations for supporting central precocious puberty patients in managing the social stigma and challenges associated with their condition.

Experts address common misconceptions about the timing of central precocious puberty treatment initiation and discontinuation, highlighting research on outcomes for therapy started before age 7 and continued beyond age 12.

Pediatric endocrinologists explore comprehensive, individualized treatment strategies for Central Precocious Puberty that extend beyond considerations of chronological and bone age.

The panel examines the efficacy and safety profiles of gonadotropin-releasing hormone analogue (GnRHa) treatments in managing Central Precocious Puberty.

Key opinion leaders analyze current treatment guidelines for Central Precocious Puberty while offering insights on navigating treatment selection in scenarios lacking established protocols.

The panel explores the impact of early versus delayed diagnosis and treatment initiation on long-term outcomes in Central Precocious Puberty patients.

Renowned specialists in central precocious puberty examine the potential psychological and social implications of CPP on affected children.

Key opinion leaders offer insights into the pathogenesis and essential features of CPP, along with additional symptoms that clinicians should monitor.

Karen O. Klein, MD, and Kent L. Reifschneider, MD, discuss a central precocious puberty (CPP) patient case regarding factors that would lead a physician to either stop treating a patient or continue with treatment.

Karen O. Klein, MD, and Kent L. Reifschneider, MD, discuss a central precocious puberty (CPP) patient case regarding factors that would lead a physician to treat a patient.

Karen O. Klein, MD, and Kent L. Reifschneider, MD, discuss individualizing treatment decisions in girls with central precocious puberty (CPP).

Karen O. Klein, MD, leads a discussion of the Vargas Trujillo et al study on the importance of individualizing treatment decisions in girls with CPP, including factors that influence the decision to begin and cease treatment.

Karen O. Klein, MD, reviews data and study results from the Vargas Trujillo et al study on the importance of individualizing treatment decisions in girls with CPP.

Karen O. Klein, MD, provides an overview of CPP (central precocious puberty) as well as a review of the study design and baseline characteristics from the Vargas Trujillo et al study on the importance of individualizing treatment decisions in girls with CPP.